Aptevo Therapeutics Inc.

Symbol: APVO




Market price today

  • 0.0868

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 4.03M

    MRK Cap

  • 0.00%

    DIV Yield

Aptevo Therapeutics Inc. (APVO) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


General Outlook

In simple terms, Aptevo Therapeutics Inc. has 11.524 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 10.084%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -8.396%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.904% return, is a testament to Aptevo Therapeutics Inc.'s adeptness in optimizing resource deployment. Aptevo Therapeutics Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 1.428%. Furthermore, the proficiency of Aptevo Therapeutics Inc. in capital utilization is underscored by a remarkable -1.427% return on capital employed.

Stock Prices

Aptevo Therapeutics Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.492, while its low point bottomed out at $0.41. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Aptevo Therapeutics Inc.'s stock market.

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Marvin L. White
Full-time employees:45
Address:2401 4th Avenue

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Aptevo Therapeutics Inc. (APVO) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is 0.087 in 2023.

What is the ticker symbol of Aptevo Therapeutics Inc. stock?

The ticker symbol of Aptevo Therapeutics Inc. stock is APVO.

What is company IPO date?

IPO date of Aptevo Therapeutics Inc. is 2016-07-20.

What is company current share price?

Current share price is 0.350 USD.

What is stock market cap today?

The market cap of stock today is 4033295.000.

What is PEG ratio in 2023?

The current 0.000 is 0.000 in 2023.

What is the number of employees in 2023?

In 2023 the company has 45.